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ABSTRACT
In many cancer types, the expression and function of ~22 nucleotide‑long 
microRNAs (miRNA) is deregulated. Mature miRNAs can be stably detected in 
extracellular vesicles (EVs) in biofluids, therefore they are considered to have great 
potential as biomarkers. In the present study, we investigated whether miRNAs have a 
distinct expression pattern in urine‑EVs of prostate cancer (PCa) patients compared to 
control males. By next generation sequencing, we determined the miRNA expression 
in a discovery cohort of 4 control men and 9 PCa patients. miRNAs were validated by 
using a stemloop RT‑PCR in an independent cohort of 74 patients (26 control and 48 
PCa‑patients). Whereas standard mapping protocols identified > 10 PCa associated 
miRNAs in urinary EVs, miR‑21, miR‑375 and miR‑204 failed to robustly discriminate 
for disease in a validation study with RT‑PCR‑detection of mature miRNA sequences. In 
contrast, we observed that miRNA isoforms (isomiRs) with 3′ end modifications were 
highly discriminatory between samples from control men and PCa patients. Highly 
differentially expressed isomiRs of miR‑21, miR‑204 and miR‑375 were subsequently 
validated in an independent group of 74 patients. Receiver‑operating characteristic 
analysis was performed to evaluate the diagnostic performance of three isomiRs, 
resulting in a 72.9% sensitivity with a high (88%) specificity and an area under the 
curve (AUC) of 0.866. In comparison, prostate specific antigen had an AUC of 0.707 
and measuring the mature form of these miRNAs yielded a lower 70.8% sensitivity 
and 72% specificity (AUC 0.766). We propose that isomiRs may carry discriminatory 
information which is useful to generate stronger biomarkers.
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INTRODUCTION
Prostate cancer is the most common form of human 
cancer, with the second cancer related cause of death in 
Western males [1]. Human prostate cancer has a complex 
etiology and despite improved knowledge in the molecular 
underpinnings of this disease, accurate diagnosis and 
targeted treatment remains challenging. Suspicion of PCa 
is generally raised when patients have elevated serum 
prostate‑specific antigen (PSA) levels, and/or abnormal 
digital rectal examination (DRE) [2]. Subsequently, 
invasive prostate tissue biopsies are required to determine 
the histological presence of prostate cancer. While 
elevated serum PSA levels above 4.0 ng/ml increases 
the risk of PCa significantly [3], increased PSA levels is 
not specific for PCa. As a consequence, about 70–80% 
of the prostate‑tissue biopsies are unnecessary [4, 5]. 
Due to the multifocal growth of PCa within the prostate, 
there is a chance that PCa is not detected even when 
multiple prostate‑tissue biopsies are taken and accurately 
examined. It has been estimated that about 20% of PCa 
cases are not detected with an initial set of biopsies, 
leading to frequent and often unnecessary repeat‑biopsies 
in patients that have no clinical disease [6]. Apart from the 
highly invasive nature of taking tumor biopsies, patients 
may develop infection (sepsis) as a consequence of the 
procedure [7]. This is becoming a concern regarding 
the increased antimicrobial resistance, despite the use 
of pre‑biopsy antimicrobial prophylaxis [7]. Therefore, 
minimally‑invasive alternatives for accurate detection of 
PCa are needed.
Recent studies indicated that extracellular vesicles 
(EVs), which are small membrane vesicles, are released by 
(prostate) cancer cells into the extracellular environment. 
Because of the anatomical location, prostate EVs can be 
found in urine [8, 9] and their levels can be increased after 
DRE [10]. Because urine can easily be collected after 
DRE, analysis of urinary‑EV content seems a promising 
approach for diagnostic testing on PCa as it has several 
advantages, notably their enrichment for miRNAs that 
can serve as PCa markers. Apart from prostate cancer, in 
many cancer types the expression of a prominent class of 
small gene regulators known as microRNAs (miRNAs) 
is consistently deregulated. The importance of miRNAs 
in PCa development is underscored by multiple studies 
that demonstrated the aberrant miRNA expression 
in PCa tissues compared to normal tissues [11–13]. 
Furthermore, miRNAs play important and unique roles 
with respect to cancer development and progression 
[14, 15]. EV‑associated miRNAs can easily be extracted 
and quantified by qRT‑PCR because they are protected 
from enzymatic degradation. miRNAs in association with 
EVs have been described to have diagnostic potential for 
(prostate) cancer patients. For example, miR‑141 and 
miR‑375 are increased in serum of metastatic prostate 
cancer patients [16–18].
Mature miRNAs are consistently annotated in the 
public registry miRBase as ~22 nucleotide‑long sequences. 
Developments in next‑generation miRNA sequencing 
analysis have revealed that in reality many miRNAs in 
biological samples exist as multiple length variants [19]. 
Such length variations are usually located at the 3′ end of 
the miRNA sequences [19]. miRNAs with terminal end 
variations are called isomiRs. IsomiRs comprise many 
modifications, including elongations, trimmings, sequence 
variants for example by editing and non‑templated 
additions (NTAs) [12]. IsomiRs are found to varying 
degrees in deep sequencing analyses depending on tissue 
origin and disease state [20]. Inexact post‑transcriptional 
processing of miRNAs is thought to be the result of 
inaccurate Drosha and Dicer processing while isomiRs 
broaden the complexity in gene‑regulatory networks. Even 
though the exact function of 3′ end modifications are still 
under investigation, increasing evidence suggests that a 
proportion of isomiRs is related to disease state possibly 
due to differences in stability and turnover [21–23]. Most 
recently, Telonis et al studied miRNA datasets from TCGA 
and demonstrated that isomiRs in breast‑cancer tissues 
can separate subtypes [23]. We previously demonstrated 
that certain miRNA modifications favor or disfavor 
their release via urinary EVs [24], a rule that may also 
apply to EVs from different sources as shown by others 
[25]. However, current knowledge of isomiRs in many 
biological settings is still nascent and as far as we know 
a potential association with (prostate) cancer has not been 
demonstrated.
In the present study, we investigated whether mature 
miRNAs and their isomiRs have a distinct expression 
pattern in urine‑EVs of PCa patients compared to control 
men, and analyzed their potential use as biomarker. Here 
we applied a next‑generation sequencing approach to 
analyze mature miRNAs and isomiR patterns using a 
recently developed comprehensive bioinformatics pipeline 
that classifies EV‑associated miRNAs including isomiRs 
[24]. In this study, we addressed the question whether 
detection of urine‑EV isomiRs can reliably report the 
presence of prostate cancer. Strikingly, our observations 
show that measuring a small panel of EV‑associated 
isomiRs provides superior clinical information over 
existing serum PSA measurements and standard detection 
of miRNAs in urine EVs. 
RESULTS
Urine EV isolation and miRNA sequencing
EVs were isolated by ultracentrifugation and 
electron microscopy pictures show urinary‑extracellular 
vesicle population with the expected size of 50–150 
nm (Figure 1A). A slight improvement was found on 
the level of background debris when EVs were isolated 
from a sucrose gradient (Figure 1A). The effect of 
Oncotarget22568www.impactjournals.com/oncotarget
storage at 4˚C, –80˚C or –80˚C cell free urine on the 
EV‑yield and structure was limited as determined by 
electron microscopy and by measuring the levels of 
vesicle markers Alix and TSG101 (Figure 1B). To test 
for the integrity of isolated EVs and to remove any 
contaminating RNA associated with cellular debris 
that may be present in EV pellet we incubated each 
sample with RNAse‑A for 1 hour at 37C. We found 
that RNAse‑A treatment had no effect on small RNA 
encapsulated in EVs as assessed by the Bioanalyzer 
small RNA chip (Supplementary Figure S1A), thus 
confirming the integrity of isolated EVs. However, at this 
point we cannot formally distinguish whether a slight 
change observed in small RNA landscape may reflect 
the RNAse‑A activity on RNA molecules ‘stuck’ to the 
outer membrane of EVs or whether a small amount of 
EVs have a damaged membrane integrity and therefore 
renders EV‑RNA accessible to RNAse‑A activity. We 
employed Illumina small RNA sequencing (PE100) as a 
method to examine the total miRNA profile in urine‑EVs 
from 13 patients, including control men, patients with 
localized PCa and patients with high‑risk PCa (the patient 
characteristics are summarized in Table 1). From these 
patient samples, we used total RNA isolated (e.g. the 
highest concentrations of RNA possible per sample) for 
RNA for library preparation (Figure 1C). A total of 28 
million raw reads were obtained (Figure 1D). Of these 
reads, about 50% could be mapped to the human genome 
with high confidence (Figure 1D) and with limited 
variation between the different samples. The reads were 
mapped to 32,000 individual loci of the human genome 
(hg19). The length distribution of the mapped miRNA 
sequences varied from 18 to 25 nt, of which most 
miRNAs were of 22 nt in length. The most abundant 
miRNA in urinary EVs of all patients was miR‑10b‑5p 
(Supplementary Table S1). miR‑10b is highly expressed 
in various tissues, including kidney and has previously 
also been observed by others in urine EVs, and also 
in EVs secreted by the PC‑3 prostate cancer cell line 
[25, 26]. The top 10 of highly expressed miRNAs was 
comparable between all patient groups (Supplementary 
Table S1). For all tested urine‑EV samples, in addition 
to miRNAs, which accounted for 44% of the aligned 
reads, we could classify all other groups of small RNAs. 
An average of 37% of the aligned reads mapped to the 
class of tRNAs, and 12% to rRNAs (Figure 1D). Small 
RNA sequences that mapped to the other ncRNAs such as 
snRNAs, snoRNAs, piRNA and repeats were represented 
by less than 2% of the total mapped reads (Figure 1D).
Candidate miRNA selection and RT‑PCR 
validation
We observed over 200 common miRNAs in 
urine‑EVs of all 13 patients analyzed. Surprisingly, 
the miRNA abundance in urine‑EVs of patients (n = 9 
patients) with confirmed PCa was lower compared to their 
relative expression in non‑cancer control (n = 4 control 
men) (Figure 1E). For accurate detection of the candidate 
miRNAs in urine‑EVs, high abundance is important to 
increase the sensitivity. In the 10 most frequent miRNAs 
that were differentially expressed (fold changed > = 2, 
(p < 0.02)) (Figure 1F), several miRNAs meeting these 
criteria were previously related to PCa [15]. To further 
verify the RNAseq expression data with an independent 
method, we examined the expression levels of 3 candidate 
miRNAs by sequence specific stem‑loop based RT‑PCR 
assay. We selected miRNAs miR‑204, miR‑375 and 
miR‑21, which had the highest expression in urine‑EVs 
of patients with PCa (Figure 1F and 2A) and were 
previously related to PCa development and progression 
[15]. The relative abundance of these three candidate 
miRNAs was determined using total RNA isolated 
from urine EVs of 74 patients by RT‑PCR. Whereas the 
results of RNAseq analysis revealed that three miRNA 
candidates are significantly differentially expressed 
between two patient groups (Figure 2A), none of those 
were differentially present between control and PCa 
patients in qRT‑PCR assay analysis (Figure 2B). Because 
the primers for qRT‑PCR were specifically directed 
towards the mature miRNA sequence (e.g. the miRBase 
annotated sequence), we analyzed the expression of the 
mature sequence in our RNAseq data. In agreement with 
the qRT‑PCR data, the reads corresponding to mature 
sequence of miR‑204, miR‑21 and miR‑375 alone were 
less differentially expressed in PCa patients compared to 
control men (Figure 2C). The most striking observation 
was for miR‑204, of which the mature sequence 
abundance was virtually the same between control and 
PCa patients and in full agreement with the qRT‑PCR 
results (Figure 2B–2C).
miRNA‑length variants as novel biomarkers
The presence of isomiRs was a common observation 
within all urine‑EV specimens (Supplementary Table S2). 
The number of isomiRs was generally increased for 
miRNAs that were more abundantly present in the urine 
EVs (Supplementary Figure S2A). miR‑204, miR‑21 and 
miR‑375 have multiple isomiRs with different lengths 
(Figure 3A). The miRNA‑read‑length of miR‑204, 
miR‑21 and mir‑375 showed clear differences when 
comparing controls with PCa patient samples (Figure 3B). 
Importantly, for miR‑204 the read length sequences of 
23 nt in length were in general the most abundant in PCa 
patients, while the 22 nt read‑length sequences were the 
most abundant sequences in samples from control men 
(Figure 3B). Furthermore, in PCa patients, a general 
decrease of all isomiRs was observed for miR‑21 and 
miR‑375.
Comparative abundance analysis of all 
miRNA‑isoforms suggested that many isomiRs are 
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differentially expressed in patients with PCa compared 
to control men. Similar as to the summed‑miRNA 
reads (Figure 1E), most of the miRNA‑isoforms were 
decreased (Figure 3C). Of the significantly changed 
miRNA‑isoforms, the occurrence of 3′‑end truncation was 
the most discriminant variant (Figure 3D, Supplementary 
Figure S2B). Furthermore, the mature miRNA was also 
commonly differentially expressed between control and 
PCa patients. With the exception of miR‑204, the isoforms 
with a fold change higher than 4 (p < 0.005) and with high 
relative abundance (> 1000 RPM) were decreased in PCa 
patients. (Figure 4A). Furthermore, specific miR‑375 
and miR‑21 isomiRs were two of the most significant 
candidates (Figure 4A).
isomiR selection and validation
For further validation whether isomiR‑specific 
analysis could improve minimally‑invasive identification 
of PCa, we selected the most discriminant isomiRs of 
miR‑204‑5p, miR‑21‑5p, and miR‑375 (Figure 4A–4C). 
These three isomiRs (Figure 4B) were measured by making 
use of custom designed stem‑loop qRT‑PCR primers 
that are optimized to recognize these isomiR‑sequences. 
We used the same patient cohort in which the mature 
miRNA sequences were measured by qRT‑PCR (Table 1). 
In agreement with the RNA sequencing data, we now 
measured a significant difference between control and PCa 
patients in abundance of the isoforms of miR‑204, miR‑21 
and miR‑375 (Figure 4C–4D).
We evaluated the performance of the three 
miRNA‑isoforms by receiver operating characteristic 
(ROC) analysis and compared the outcome with 
that of ROCs calculated based on the measurement 
of mature miRNAs alone. For PSA the predictive 
accuracy (AUC) was 0.707, which is highly similar 
to what has been determined before in large patient 
cohorts [27] (Figure 4E). The predictive accuracy for 
prostate cancer was decidedly higher for the combined 
set of isomiRs (AUC 0.821), compared to that of the 
mature‑miRNA panel alone (AUC 0.661) (Figure 4E). 
The predictive accuracy could be improved further when 
combining with sPSA to an AUC of 0.866 and 0.766, 
for the isomiR‑set and mature miRNA‑set, respectively 
(Figure 4F). For PSA alone, a concentration of 7.5 ng/ml 
was the cutoff point that maximized the sensitivity 
(70.8%) and specificity (60.0%) for the detection of 
PCa. However, when considering 4 ng/ml as cutoff point, 
the sensitivity for the detection for PCa was 85.4% and 
specificity only 32.0%. When decreasing PSA cutoff to 
3 ng/ml, this was 95.8% and 24.0%, respectively. On the 
basis of the predictor model for the sets of 3 isomiRs, a 
probability of 0.77 was the cutoff point that maximized 
the sensitivity (72.9%) and specificity (88%) for the 
detection of PCa in urine‑EVs. At this cutoff point, 
the positive predictive value (PPV) was 92.1% and the 
negative predictive value (NPV) was 62.9%. For the 
combined miRNAs at the optimized cut‑off point of 0.68 
resulted in a lower sensitivity (70.8%) and specificity 
(72.0%) for the detection of PCa in urine‑EVs, compared 
to that of the isomiR‑set. At this cutoff point, PPV was 
54.8% and the NPV was 81.0%, which is much lower 
than the isomiR‑panel, showing the strength the selected 
isomiRs in detection of PCa.





Total number 13 74










PSA*, median (range) 9.5 (3.9–703) 8.5 (1–424)
*Age (year), T‑staging and PSA levels (ng/ml) at time of diagnosis.
**Gleason score after radical prostatectomy tissue or biopsy tissue (when no prostatectomy has been performed).
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Figure 1: Urine‑EV RNA sequencing. (A) EM pictures of EVs isolated by ultra‑centrifugation. Urine stored as full urine, centrifuged 
over sucrose gradient, after storage as cell free fraction and storage at 4˚C. Scale bar = 100 nm. (B) Western blot showing vesicle markers 
Alix and TSG101 in isolated EV‑fractions. (C) Representative urine‑EV small RNA bioanalyzer profile selected for smallRNA sequencing. 
(D) Deep sequencing results overview including the number of reads, mapped sequencing reads and distribution of mapped reads between 
different ncRNA classes. miRNA (415665 RPM), tRNA fragments (356709 RPM), rRNA fragments (110889 RPM), Y‑RNA fragments 
(41347 RPM), mRNA fragments (8253 RPM), repeat fragments (18632 RPM), and fragments of miscellaneous non‑coding RNAs (3028 
RPM). (E) Volcano plot showing differences between urine‑EV miRNAs of control men (n = 4) and cancer (n = 9) patients miRNAs were 
classified according to the fold changes (log2 FC), between control men and cancer patients. Vertical dotted lines: miRNA with > 2 fold 
enrichment in control men or cancer patient urine EVs. (F) Top 15 highly expressed miRNAs expressed > 2 fold and p < 0.02 between 
control and cancer patients. miRNAs selected for further analysis are indicated in red.
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DISCUSSION
In the present study we demonstrate that urine EVs 
can be used for minimally invasive tests to detect PCa 
in suspect individuals. We show that isomiRs present 
in urinary EVs, more so than mature miRNA sequences 
are able to detect prostate cancer in suspected patients. 
Specifically, we identified isomiRs of miR‑21, miR‑375 
and miR‑204 that distinguish controls from PCa patients. 
Using receiver operating characteristic (ROC) analysis we 
calculated an AUC of 0.821 based on these three isomiRs 
combined with PSA, showing the potential of these 
isomiRs for minimally‑invasive testing on PCa.
The discovery that miRNAs are sorted into EVs, 
both by healthy and by cancer cells, has become a general 
observation made in many laboratories [28, 29]. The 
applicability of EV‑associated nucleic acids, including 
miRNAs for diagnostic purposes is gaining increasing 
interest from both clinicians and pharmaceutical 
industry that seek minimally‑invasive diagnostics [30]. 
A large variety of biofluids such as blood, seminal fluid, 
breast milk, sputum, cerebrospinal fluid and also urine 
are known to contain (secreted) miRNAs. Urine is an 
attractive biofluid as its collection is non‑invasive and 
contains a high concentration of EVs produced by a 
selected group of organs (prostate, bladder, kidneys and 
urothelial cells). This is in contrast with blood serum and 
plasma as biofluids that contain EVs from all organs of 
the body and are dominated by platelet‑derived vesicles 
[31]. However, in some patients the EVs yield was 
extremely low, even though all patients had received 
DRE. This rate is comparable to observations of others 
[10, 27, 32, 33]. Counter intuitively this may, in part, be 
related to higher amount of liquid consumption. This has 
previously been described in studies that analyzed urine 
[27] and sediments [34]. Fluid restriction may lead to an 
Figure 2: Detection of mature miRNAs is unreliable for validation of RNA sequencing data. (A) Boxplot of the 
RNA‑sequencing expression (RPM) of the three selected miRNAs, miR‑204, miR‑21 and miR‑375. (B) Boxplot showing failure to 
validate (RT‑PCR) the three miRNAs. The data was normalized by ΔCt analysis to control‑reference sample, after which the values were 
transformed to natural‑log. (C) Boxplot showing the expression of the mature miRNA sequence that was detected by RT‑PCR, showing a 
more similar result as obtained for the RT‑PCR detection of the mature‑miRNA.
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increase in EV yield. Furthermore, it has been suggested 
that pre‑amplification procedures prior to RT‑PCR may 
increase the cDNA number and thereby improve the 
detection [33].
With a genome‑wide small RNA (Illumina) 
sequencing analysis, we were able to identify numerous 
small RNA species present in urine EVs. Apart from the 
identification of well annotated miRNA‑related sequences, 
the other dominant small RNA sequences mapped to 
human genome appear to be short fragments of known 
RNA classes such as tRNA, rRNA, Y RNA and mRNA. 
The presence of tRNA fragments in urine and sera of 
cancer patients has been previously documented [35] and 
seems to correlate with high turnover of tRNAs in cancer 
tissue. Although the tRNA fragments are present in high 
amounts in prostate biopsies from metastatic patients [36] 
Figure 3: miRNA repertoire consists of multiple length variants. (A) Examples of miRNA stem loop strucewtures with mature 
miRNA location in blue. Small RNAseq detected sequences of post‑transcriptionally processed isomiRs belonging to miR‑204, miR‑21 and 
miR‑375. Bold nucleotides represent NTA. (B) Relative size distribution of the isomiRs of miR‑204, miR‑21 and miR‑375 showing a clear 
change in expression of length‑variants. (C) Volcano plot showing larger differences between urine‑EV isomiRs of control men and cancer 
patients compared to the summed‑miRNAs. isomiRs were classified according to the fold changes (log2 FC), between control men and 
cancer patients. Vertical dotted lines: isomiR with > 2 fold enrichment in control men or cancer patient urine EVs. (D) Compared to control 
men, EVs derived from PCa‑patients show differences in the occurrence of miRNA‑processing. The isoform‑occurrence was calculated by 
summing the significantly changed isomiR types (e.g. mature, truncation, etc). Most notable number of changed variants that were related 
to PCa were truncation, elongation and non‑templated nucleotide additions (e.g. NTA‑A and NTA‑U).
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Figure  4:  isomiRs  improve  the  specificity  for detecting PCa.  (A) Expression of the top 15 isoforms. Isoforms of miR‑204, 
miR‑21, and miR‑375 were highly abundant and significant. *p < 0.05, **p < 0.01, ***p < 0.001. (B) mature and isomiR sequences of 
miR‑204, miR‑375 and miR‑21 that were selected. (C) Boxplot showing the abundance of the isomiRs belonging to miR‑204, miR‑21 and 
miR‑375 by RNA sequencing. (D) RT‑PCR validation of the expression of the isomiRs, showing significant differences between control 
men and cancer patients. (E) ROC curves for the combination of the urine‑EV isomiRs (blue line), compared to the mature sequence (grey 
line) and PSA, (orange line). (F) ROC curves for the combination of PSA with 3 urine‑EV isomiRs (blue line), compared to the mature 
sequence (grey line) and PSA, (orange line).
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and their generation may be androgen‑dependent [37], 
the molecular basis behind their biogenesis, function and 
potential use as biomarker in urinary EVs remains to be 
further elucidated.
During the analysis of small RNA class distribution, 
we observed that small RNA sequences belonging to 
miRNA class exhibited the most significant deregulation 
between samples of control men and PCa patients. Among 
those we identified miRNA sequence variants commonly 
referred to as isomiRs [38]. Although the biological 
relevance of isomiR expression in cancer development 
and progression is not well understood, we found that 
isomiRs are present at different relative frequencies in 
urine EVs of PCa patients compared to urine EV samples 
from control men. An additional conclusion of this study 
is that detection of mature miRNA sequences as listed 
in miRBase using dedicated stemloop RT‑PCR does not 
always correspond with RNAseq results. This seems 
to depend on the analysis thresholds that are applied 
and could explain why some miRNAs fail as cancer 
biomarkers in validation studies [39]. This underlines the 
importance of analyzing the presence and abundance of 
certain isomiRs when validation by stemloop RT‑PCR 
is preferred [38]. Even though the stem‑loop PCR 
primer method is in theory useful for detecting defined 
3′‑end isomiR‑sequences, cross‑detection of related 
miRNA sequences may occur [38]. Importantly, the 
isomiRs that we selected in this study as potential PCa 
biomarkers were selected for their differential abundance 
in urinary samples obtained from high‑throughput 
sequencing data. We validated the RNA‑sequencing data 
observed differences in abundance for isomiRs and their 
mature forms using stemloop primers [40]. In general, 
we measured several‑fold differences in abundance 
between the mature vs isomiRs in concordance with 
the RNA‑sequencing read abundance, suggesting that 
cross‑detection is probably does not have a significant 
impact on the PCR measurements. A small percentage of 
cross‑detection may still occur, and can therefore not be 
excluded at this stage. We previously reported that many 
miRNAs are generally comparably expressed in (tumor) 
cells and detected in their secreted EVs, while other 
miRNAs show specific cellular retention or abundance in 
EVs [24]. More specifically, we found that 3′uridylated 
miRNAs are more abundant in EVs than could be 
expected from their relative abundance in producing 
tumor cells. In contrast, miRNAs that are 3′adenylated 
are generally underrepresented in EVs compared to their 
relative expression within the cells [24]. This disruption 
is emphasized by a recent observations by Boele et al 
[41], which described that the poly(A) polymerase 
PAPD5‑mediated adenylation of miRNA‑21 is disrupted in 
cancer. A disruption of post‑transcriptional processing of 
miRNAs can affect their stability, activity, RISC‑loading 
potential, turnover, or affect their enrichment in secreted 
EVs, and as a consequence measuring of isomiRs may 
be useful for cancer‑specific detection. Notably, the 
study by Boele and colleagues could explain why several 
PCa‑related miRNAs are actually less abundant in urine 
EVs even though these are upregulated in cancer tissues. 
Furthermore, these decreased PCa‑related miRNAs 
in urine were also observed previously by Sapre et al. 
[39]. Additional studies are essential to determine the 
physiological significance of post‑transcriptional miRNA 
modifications, EV sorting and the role of these processes 
in cancer development and usefulness for liquid biopsy 
tests. The modifications such as non‑templated nucleotide 
additions are generated by RNA‑modifying enzymes 
called ribonucleotidyl transferases (rNTAs) but their role 
in cancer remains largely unexplored.
In conclusion, in this study we demonstrate 
that detection of EV‑associated isomiRs could allow 
minimally‑invasive diagnosis of PCa patients. If validated 
in larger follow up studies, the isomiRs identified in this 
study could be useful to predict which patients suspected of 
PCa require a tissue biopsy and which patients are unlikely 
to suffer from PCa and may continue minimally‑invasive 
monitoring. Addition of our isomiR panel to existing 
urinary tests (i.e. PCA3, Quattro, ERG) [27, 42] or those in 
development, may improve the detection accuracy for PCa.
MATERIALS AND METHODS
Urine and extracellular vesicle collection and 
isolation procedures and transmission electron 
microscopy (TEM)
For optimization experiments, urine was collected 
from healthy individuals and stored at 4˚C (7 days), at 
–80˚C (7 days) or alternatively centrifuged (500 × g 
and 2000 × g) at 4˚C before –80˚C storage. For miRNA 
expression analysis, we collected 20–90 ml of urine from 
patients (from July 2012) diagnosed with prostate cancer 
(Gleason score was adjusted when prostate surgery was 
performed) or control men (without prostate cancer, 
confirmed by biopsy). Men who were scheduled for initial 
or repeat prostate biopsies, based on elevated PSA levels 
or abnormal DRE were included. Risk‑classification 
was performed according to D’Amico [43]. First catch 
urine after DRE was collected. Exclusion criteria were 
previous medical therapy against prostate hyperplasia, 
chemotherapy, presence of any other cancer type, any 
previous therapy concerning the prostate (e.g. TURP). 
Urine was collected after signed informed consent 
and approval of the medical ethical committee of the 
VU University Medical Center and stored at –80˚C. 
About 20–90 ml of urine was used for EV isolation, 
and urine‑EVs were isolated by differential (ultra)
centrifugation (UC) as described previously [8]. In brief, 
urine was centrifuged at 20000 × g for 30 min at 4˚C to 
remove the debris. The supernatant was subsequently 
used for EV isolation by ultracentrifugation at 100000 × g 
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for 90 min at 4˚C. The EV pellet was washed in PBS and 
subsequently centrifuged again at 100000 × g for 90 min 
at 4˚C. When sucrose was used, the EV pellet was 
dissolved in 30% sucrose and layered on top of 40% 
sucrose. The exosome layer was extracted from the 
interfaces, and pelleted at 100000 × g ultracentrifugation 
for 90 min. Directly after centrifugation, EVs were treated 
with RNAse‑A (4 µg/ml at 37˚C for 1 h). Treatment 
with RNAse‑A hardly affected the small RNA profile as 
determined with Agilent bioanalyzer small RNA chips 
(Supplementary Figure S1). Ultrastructural evaluation 
of urine‑EVs was performed by transmission electron 
microscopy (TEM) as described previously [24].
Protein analyses
Western blot was performed as described previously 
[8]. The membranes were incubated with mouse anti‑Alix 
(1:500; #2171, Cell Signaling) or goat anti‑TSG101 
(1:1000; #sc‑7964, Santa Cruz Biotechnology, USA).
Preparation of RNA samples and library 
construction for deep sequencing
Total RNA was isolated from 13 patients (Table 1) 
using Trizol LS, according to manufacturer’s instruction 
and small RNA concentration was determined using a 
small RNA Bioanalyzer Chip (Agilent, Santa Clara, CA, 
USA). Preparation and sequencing of cDNA libraries was 
performed using 200–600 ng of small RNA from total 
RNA samples, according to manufacturer’s instruction 
(Illumina, San Diego, CA, USA) and was performed as 
described previously [24]. In brief, 13 unique barcode 
sequences were applied for simultaneous analysis of 
multiple samples on one lane. The cDNA sequence library 
yield were measured on an Agilent 2100 Bioanalyzer 
(Agilent) and the samples were pooled in equimolar 
concentrations for the sequencing run. Sequencing was 
performed paired end 100 (PE100) cycles on a HiSeq 2000 
(Illumina).
Data processing deep miRNA sequencing
The expression profiling of miRNAs was performed 
by means of the sRNA toolbox implementation of 
sRNAbench, which is the successor of miRanalyzer as 
described previously [24, 44, 45]. In brief, the processing 
of the fastq format files included adapter trimming, 
deletion of reads < 15 nt, and to collapse all reads with 
identical sequences into one entry (unique reads). The 
read count assigned to each unique read represents the 
number of times the corresponding molecule has been 
sequenced. The reads were aligned using two approaches: 
all reads alignment to the human genome (hg19 from 
UCSC), using the bowtie seed alignment allowing one 
mismatch or all reads annotation by using known RNA 
databases (to assign reads to different RNA classes). 
Using one mismatch approach of mapping to the human 
genome, the seed alignment method avoids that strongly 
modified molecules (e.g. isomiRs) fail to map, which 
would impede their detection [45]. Finally, we calculated 
the RPM (Reads Per Million) expression value for 1. 
Mature miRNA sequences as sum of all reads that map 
to a specific miRNA and 2. Individually assigned miRNA 
sequences (canonical or per isoform type) using the total 
number of miRNAs mapped reads for normalization. This 
value is therefore independent of the total read yield of the 
sample and it is not affected by the relative frequency of 
other small RNAs.
Statistical analysis NGS data
To compare abundance for each miRNA between 
different patient groups, the observed counts were 
fitted in a generalized linear model using the R package 
edgeR [46]. The model included not only common 
and trend dispersion, but also tagwise dispersion 
estimation, allowing thus for extra variability due to 
inter‑library fluctuation. The p‑values corresponding 
to the likelihood‑ratio test statistic for the sample 
type effect were corrected for multiple testing using 
Benjamini‑Hochberg’s false discovery rate. We calculated 
the log2 ratios of expression values between control group 
and PCa‑patient group, and candidate miRNAs were 
selected based on log2 > = 1, and p‑value < = 0.05. The 
miRNA‑isoform occurrence was determined by summing 
the times an isoform of specific type (e.g. trimming, 
elongation, 5′‑modification, non‑templated nucleotide 
additions (NTA) NTA‑U, NTA‑A, NTA‑G, NTA‑C and 
mature sequence) was present in the urine‑samples that 
were significantly changed > = 2 fold difference.
RT‑PCR
Urine EV‑RNA (50 ng/sample) from 74 patients 
(Table 1) was used for reverse transcriptase, which was 
performed according to manufactures instruction (Life 
Technologies). Primers used were miRNA assays from 
Life Technologies # 4427975 for the mature sequences. For 
Custom primers, Life Technology primers were ordered, 
miR‑21‑5p‑isomiR (UAGCUUAUCAGACUGAUGUU) 
#4398987, miR‑375‑isomiR (UUUGUUCGUUCGGCUCG 
CGUG) #4398987, miR‑204 isomiR (UUCCCUUU 
GUCAUCCUAUGCCUG) #440886. RT‑PCR was 
performed using 3 µl of diluted cDNA, according to 
manufacturer’s instruction using Light Cycler (Roche). 
Analysis on expression data of the selected miRNAs 
by RT‑PCR were performed with SPSS version 20.0 
and with edgeR [46]. The cDNA of control samples was 
pooled and used as a reference. The data was normalized 




Statistical differences between patient groups was 
performed in SPSS20.0 and values were considered 
significantly differentially expressed when P < 0.05. 
Normalized RT‑PCR data were used to classify samples 
according to disease status (healthy vs. cancer) by 
means of a logistic model. Five different models were 
considered according to the covariates included: PSA as 
the only covariate; the set of 3 mature miRNAs; the set 
of 3 mature miRNAs plus PSA; the set of 3 isomiRs; and 
the set of 3 isomiRs plus PSA. Each model was used to 
classify patients using a leave‑one‑out cross‑validation 
(LOOCV) approach. This involved leaving one patient 
out of the data at a time, then fitting the model to the 
patients included, and subsequently computing the 
predicted probability of disease for the patient that was 
left out. All predicted probabilities were computed per 
model, ROC curves were constructed by varying the 
threshold above which a sample is classified as having 
the disease between 0.01 and 0.99. For each possible 
threshold value, sensitivity and specificity are computed. 
From the ROC curves, areas under the curve (AUC) were 
determined.
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